Evaluation of circulating microRNAs as non-invasive biomarkers in the diagnosis of ovarian cancer: a case-control study.
Acidosis
Disease biomarker
Hypoxia
Liquid biopsies
Ovarian cancer
Urinary microRNAs
Urine
microRNAs
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
21
12
2020
accepted:
13
10
2021
pubmed:
11
12
2021
medline:
23
7
2022
entrez:
10
12
2021
Statut:
ppublish
Résumé
Ovarian cancer is the seventh most frequent form of malignant diseases in women worldwide and over 150,000 women die from it every year. More than 70 percent of all ovarian cancer patients are diagnosed at a late-stage disease with poor prognosis necessitating the development of sufficient screening biomarkers. MicroRNAs displayed promising potential as early diagnostics in various malignant diseases including ovarian cancer. The presented study aimed at identifying single microRNAs and microRNA combinations detecting ovarian cancer in vitro and in vivo. Intracellular, extracellular and urinary microRNA expression levels of twelve microRNAs (let-7a, let-7d, miR-10a, miR-15a, miR-15b, miR-19b, miR-20a, miR-21, miR-100, miR-125b, miR-155, miR-222) were quantified performing quantitative real-time-PCR. Therefore, the three ovarian cancer cell lines SK-OV-3, OAW-42, EFO-27 as well as urine samples of ovarian cancer patients and healthy controls were analyzed. MiR-15a, miR-20a and miR-222 showed expression level alterations extracellularly, whereas miR-125b did intracellularly across the analyzed cell lines. MicroRNA expression alterations in single cell lines suggest subtype specificity in both compartments. Hypoxia and acidosis showed scarce effects on single miRNA expression levels only. Furthermore, we were able to demonstrate the feasibility to clearly detect the 12 miRNAs in urine samples. In urine, miR-15a was upregulated whereas let-7a was down-regulated in ovarian cancer patients. Intracellular, extracellular and urinary microRNA expression alterations emphasize their great potential as biomarkers in liquid biopsies. Especially, miR-15a and let-7a qualify for possible circulating biomarkers in liquid biopsies of ovarian cancer patients.
Identifiants
pubmed: 34889994
doi: 10.1007/s00404-021-06287-1
pii: 10.1007/s00404-021-06287-1
pmc: PMC9300512
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-163Informations de copyright
© 2021. The Author(s).
Références
Oncotarget. 2015 Nov 3;6(34):36815-24
pubmed: 26416421
Br J Cancer. 2015 Nov 3;113(9):1358-66
pubmed: 26393886
BMC Cancer. 2015 Mar 28;15:193
pubmed: 25886191
J Clin Diagn Res. 2012 Dec;6(10):1791-5
pubmed: 23373057
Biochim Biophys Acta. 2010 Dec;1806(2):200-7
pubmed: 20637263
Clin Cancer Res. 2013 Aug 1;19(15):4114-23
pubmed: 23766361
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
Cancer Res. 2008 Jan 15;68(2):425-33
pubmed: 18199536
J Int Med Res. 2013 Feb;41(1):64-71
pubmed: 23569131
Ann Surg. 2010 Mar;251(3):499-505
pubmed: 20134314
BMC Cancer. 2012 Dec 28;12:627
pubmed: 23272653
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Endocr Relat Cancer. 2010 Jan 29;17(1):F77-89
pubmed: 19903743
Clin Cancer Res. 2008 May 1;14(9):2690-5
pubmed: 18451233
J Obstet Gynaecol Can. 2004 Aug;26(8):717-28
pubmed: 15307976
Gynecol Oncol. 2009 Jan;112(1):55-9
pubmed: 18954897
Tumour Biol. 2015 Jun;36(6):4843-50
pubmed: 25636451
Cell. 2005 Mar 11;120(5):635-47
pubmed: 15766527
Oncol Rep. 2017 Aug;38(2):993-1004
pubmed: 28627686
Br J Cancer. 2014 Feb 18;110(4):976-83
pubmed: 24366298
Br J Cancer. 2010 Aug 24;103(5):693-700
pubmed: 20683447
Cancer Res. 2007 Sep 15;67(18):8699-707
pubmed: 17875710
Mol Cell Biol. 2007 Mar;27(5):1859-67
pubmed: 17194750
J Ovarian Res. 2014 Jan 25;7:14
pubmed: 24460816
Cancer Res. 2006 Aug 1;66(15):7390-4
pubmed: 16885332
PLoS One. 2013 Nov 01;8(11):e77853
pubmed: 24223734
Tumour Biol. 2015 Jul;36(7):5305-13
pubmed: 25722112
J Exp Clin Cancer Res. 2016 Jun 27;35:103
pubmed: 27349385
PLoS One. 2008 Jun 18;3(6):e2436
pubmed: 18560586
Nat Commun. 2016 May 05;7:11406
pubmed: 27147225
Gynecol Oncol. 2008 Jul;110(1):13-21
pubmed: 18589210
Clin Transl Oncol. 2015 Oct;17(10):779-87
pubmed: 26063644
Clin Cancer Res. 2013 Mar 1;19(5):1213-24
pubmed: 23362326
J Clin Pathol. 2005 Mar;58(3):308-12
pubmed: 15735166
Tumour Biol. 2017 May;39(5):1010428317695525
pubmed: 28459207
J Cell Mol Med. 2014 Mar;18(3):371-90
pubmed: 24533657
Methods. 2010 Apr;50(4):298-301
pubmed: 20146939
Mol Cancer. 2016 Jun 24;15(1):48
pubmed: 27343009
Int J Gynecol Cancer. 2013 May;23(4):673-9
pubmed: 23542579
Cancer Sci. 2011 Mar;102(3):522-9
pubmed: 21166959
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9
pubmed: 18458333
PLoS One. 2009;4(4):e5311
pubmed: 19390579
Am J Cancer Res. 2015 Oct 15;5(11):3455-66
pubmed: 26807325
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Pathol Oncol Res. 2015 Sep;21(4):1027-35
pubmed: 25827090
Oncol Rep. 2015 Jun;33(6):2915-23
pubmed: 25962395
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Nat Commun. 2013;4:2427
pubmed: 24018975
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9845-50
pubmed: 23697367
Cardiovasc Res. 2016 Sep;111(4):322-37
pubmed: 27357636
J Rheumatol. 2010 Dec;37(12):2516-22
pubmed: 20952466
Cancer Biol Ther. 2008 Feb;7(2):255-64
pubmed: 18059191
Pathobiology. 2018;85(1-2):41-49
pubmed: 29020678
Chin Med J (Engl). 2015 Dec 20;128(24):3363-70
pubmed: 26668153